Allan Oberman

Chief Executive Officer

Mr. Oberman brings more than 15 years of international pharmaceutical industry experience to Concordia including his recent role as Chief Executive Officer of specialty pharmaceutical company Sagent Pharmaceuticals, Inc. Sagent was sold to Nichi-Iko Pharmaceutical Co. Ltd., Japan’s largest generic drug manufacturer, in a transaction that closed on August 29, 2016. Prior to Sagent, from November 2012 to December 2014, Mr. Oberman served as President and CEO of Teva Americas Generics, a region which included the U.S., Canada and Latin America. He joined Teva in 2000 and served as President of Teva EMIA (Eastern Europe, Middle East, Israel and Africa), where he led a diverse group of countries in achieving consistent sales growth. Mr. Oberman also served as the Chief Operating Officer of Teva International, and President and CEO of Teva Canada, formerly known as Novopharm Limited.

Edward Borkowski

Chief Financial Officer

Mr. Borkowski is a healthcare executive who previously was the CFO of Amerigen Pharmaceuticals, a generic pharmaceutical company with a focus on oral controlled release products. Prior to working with Amerigen, he was the CFO and Executive Vice President of Mylan N.V. In addition, Mr. Borkowski previously held the position of CFO with Convatec, a global medical device company focused on wound care and ostomy, and Carefusion, a global medical device company for which he helped lead its spin-out from Cardinal health into an independent public company. Mr. Borkowski also held senior financial positions at Pharmacia and American Home Products (Wyeth). He started his career with Arthur Andersen & Co. after graduating from Rutgers University with an MBA in accounting. Mr. Borkowski also graduated from Allegheny College with a degree in Economics and Political Science. He is a Trustee and an Executive Committee member of Allegheny College.

Wayne Kreppner

President & Chief Operating Officer

Prior to joining Concordia, Mr. Kreppner served as Vice-President of Product Development at Trimel Pharmaceuticals Inc. As a co-founder of Trimel, Mr. Kreppner was responsible for all Scientific Operations including R&D, Clinical Development, Manufacturing and Supply Chain. Prior to Trimel, Mr. Kreppner held various senior roles in Operations and Regulatory Affairs with Biovail Pharmaceuticals Inc. from 1997 until 2008, where he most recently served as Vice President, Technology Transfer.

Mr. Kreppner holds a Hons. B.Sc. degree in Biochemistry from the University of Western Ontario, an M.Sc. in Medical Science from McMaster University and an MBA from the Ivey School of Business, University of Western Ontario.

Francesco Tallarico

Chief Legal Officer and Secretary

Mr. Tallarico is Chief Legal Officer and Secretary of Concordia International Corp. Mr. Tallarico manages the Global legal function of the Corporation. Prior to joining the Corporation in 2014, Mr. Tallarico practiced law at Fasken Martineau DuMoulin LLP, an international law firm based out of Toronto, Ontario, with a particular focus on corporate governance, corporate finance and M&A transactions. During his time with the Corporation, Mr. Tallarico has been actively involved and instrumental in various M&A transactions valued at over $4.5 billion. Mr. Tallarico holds a B.A. from the University of Toronto and a J.D. from the University of Windsor.

Graeme Duncan

President of Concordia’s International segment

Mr. Duncan is President of Concordia’s International segment. Mr. Duncan joined Amdipharm Mercury Limited (now Concordia’s International segment) in 2015 as Global Marketing Director and Vice President, Commercial UK and Ireland. He was promoted to Managing Director in 2016 and was responsible for the general management of the segment. Mr. Duncan has worked for 20 years in the life sciences sector within the areas of strategy, sales and marketing, and management. Prior to Concordia, Mr. Duncan held senior management roles in GlaxoWellcome, GlaxoSmithKline, IVAX Pharmaceuticals and Healthcare at Home.